ACE-536
Showing 1 - 25 of 545
Anemia Trial (Luspatercept)
Not yet recruiting
- Anemia
- Luspatercept
- (no location specified)
May 26, 2023
MDS Trial in Houston (Luspatercept)
Not yet recruiting
- Myelodysplastic Syndromes
-
Houston, TexasM D Anderson Cancer Center
Nov 2, 2023
Myelodysplastic/Myeloproliferative Tumor With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Tumor,
Recruiting
- Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
- Hydroxyurea
- Luspatercept
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 6, 2023
Anemia Trial in Worldwide (biological, drug, other)
Recruiting
- Anemia
- Luspatercept
- +2 more
-
Halifax, Nova Scotia, Canada
- +11 more
Jan 3, 2023
MDS, Myeloproliferative Tumor, Anemia Trial in Tampa (Luspatercept)
Recruiting
- Myelodysplastic Syndromes
- +2 more
-
Tampa, FloridaMoffitt Cancer Center
Feb 16, 2023
MDS Trial in Dresden (ACE-536)
Completed
- Myelodysplastic Syndromes
- ACE-536
-
Dresden, GermanyAcceleron Investigative Site
Apr 29, 2021
Anemia Trial in Dresden (ACE-536)
Completed
- Anemia
- ACE-536
-
Dresden, GermanyAcceleron Investigative Site
Apr 29, 2021
Beta-Thalassemia Trial in Greece, Italy (ACE-536)
Completed
- Beta-Thalassemia
- ACE-536
-
Athens, Greece
- +6 more
May 17, 2021
Thalassemia Trial in Worldwide (Luspatercept, Placebo, Best Supportive Care (BSC))
Active, not recruiting
- Thalassemia
- Luspatercept
- +2 more
-
Los Angeles, California
- +16 more
Aug 16, 2022
MDS Trial in Worldwide (Luspatercept)
Not yet recruiting
- Myelodysplastic Syndromes
-
Los Alamitos, California
- +53 more
Sep 13, 2023
Erythrocyte Transfusion, Beta-Thalassemia Trial in Worldwide (Luspatercept, Placebo)
Completed
- Erythrocyte Transfusion
- Beta-Thalassemia
- Luspatercept
- Placebo
-
Los Angeles, California
- +72 more
Jan 21, 2022
MDS Trial in Worldwide (Luspatercept, Placebo)
MDS, MDS Trial in France (Luspatercept Injection [Reblozyl], Eprex)
Recruiting
- MDS
- Myelodysplastic Syndromes
- Luspatercept Injection [Reblozyl]
- Eprex
-
Amiens, France
- +30 more
May 19, 2022
MDS (MDS), Beta-thalassemia, Myeloproliferative Tumor(MPN)-Associated Myelofibrosis Trial in Worldwide (Luspatercept)
Recruiting
- Myelodysplastic Syndromes (MDS)
- +2 more
-
Los Angeles, California
- +203 more
Jan 30, 2023
MDS Trial in Worldwide (Luspatercept, Epoetin Alfa)
Not yet recruiting
- Myelodysplastic Syndromes
- Luspatercept
- Epoetin Alfa
-
Concord, California
- +100 more
Jul 20, 2023
Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis Trial in Worldwide (ACE-536, Placebo)
Recruiting
- Myeloproliferative Disorders
- +4 more
- ACE-536
- Placebo
-
La Jolla, California
- +184 more
Aug 22, 2022
MDS, Del(5Q), Anemia Trial in Italy (Luspatercept Injection [Reblozyl])
Recruiting
- Myelodysplastic Syndromes
- +3 more
- Luspatercept Injection [Reblozyl]
-
Alessandria, Italy
- +22 more
Jun 20, 2023
MDS Trial in Beijing (Roxadustat, Luspatercept)
Not yet recruiting
- Myelodysplastic Syndromes
-
Beijing, ChinaPeking union medical college hospital
Aug 17, 2023
Keloid Scar Trial (Intralesional enalaprilat injection)
Not yet recruiting
- Keloid Scar
- Intralesional enalaprilat injection
- (no location specified)
Jun 8, 2022
Minimisation Measures for REBLOZYL Among Healthcare
Active, not recruiting
- Myelodysplastic Syndromes
- Beta-thalassemia
-
City, State, AustriaLocal Institution
Aug 4, 2022